Skip to main content
. 2019 Dec 4;10(12):911. doi: 10.1038/s41419-019-2141-9

Fig. 5. USP22 deficiency conveys therapeutic vulnerability towards HSP90i in vivo.

Fig. 5

a In a xenograft approach, USP22+/+ and USP22−/− HCT116 cells were injected subcutaneously into immunodeficient mice and treated with Ganetespib or vehicle (n = 6 per group). Results obtained from one representative wild type and USP22 knockout clone are shown. While Ganetespib treatment displayed minor effects on USP22 wild type tumors, b the accelerated growth of USP22−/− tumors was significantly impaired by HSP90 inhibition to levels below that of treated USP22+/+ tumors. Blue arrow heads indicate the days on which Ganetespib was administered. Mean ± SEM, Student’s t-test. c Representative images of USP22+/+ and USP22−/− tumors after the treatment with Ganetespib or vehicle. Scale bar: 1 cm. d, e As detected by IHC, the number of proliferating Ki67-positive cells in USP22−/− tumors upon HSP90 inhibition was significantly decreased compared to tumors isolated from vehicle-treated mice. Mean ± SEM, one-way ANOVA. Scale bar: 100 µm.